SG11202009724YA - Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase - Google Patents
Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinaseInfo
- Publication number
- SG11202009724YA SG11202009724YA SG11202009724YA SG11202009724YA SG11202009724YA SG 11202009724Y A SG11202009724Y A SG 11202009724YA SG 11202009724Y A SG11202009724Y A SG 11202009724YA SG 11202009724Y A SG11202009724Y A SG 11202009724YA SG 11202009724Y A SG11202009724Y A SG 11202009724YA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrazolo
- triazine
- dependent kinase
- selective inhibitor
- pyrimidine derivatives
- Prior art date
Links
- RXQZLSRIOOYKLF-UHFFFAOYSA-N 5H-pyrazolo[4,3-d]triazine Chemical compound N1=NN=C2C=NNC2=C1 RXQZLSRIOOYKLF-UHFFFAOYSA-N 0.000 title 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 title 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656070P | 2018-04-11 | 2018-04-11 | |
| PCT/EP2019/059302 WO2019197549A1 (en) | 2018-04-11 | 2019-04-11 | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202009724YA true SG11202009724YA (en) | 2020-10-29 |
Family
ID=66334385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202009724YA SG11202009724YA (en) | 2018-04-11 | 2019-04-11 | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11945822B2 (es) |
| EP (1) | EP3774810A1 (es) |
| JP (2) | JP2021521120A (es) |
| KR (1) | KR20200141487A (es) |
| CN (1) | CN112313235A (es) |
| AU (1) | AU2019250507B2 (es) |
| BR (1) | BR112020020768A2 (es) |
| CA (1) | CA3095880A1 (es) |
| IL (1) | IL277770B2 (es) |
| MX (1) | MX2020010675A (es) |
| PH (1) | PH12020551639A1 (es) |
| SG (1) | SG11202009724YA (es) |
| WO (1) | WO2019197549A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220144841A1 (en) * | 2019-03-13 | 2022-05-12 | The Translational Genomics Research Institute | Trisubstituted pyrazolo [1,5-a] pyrimidine compounds as cdk7 inhibitors |
| TW202146416A (zh) * | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | 吡唑并三𠯤 |
| GB201918541D0 (en) | 2019-12-16 | 2020-01-29 | Carrick Therapeutics Ltd | Therapeutic compounds and their use |
| AU2020404326A1 (en) | 2019-12-20 | 2022-08-11 | Evopoint Biosciences Co., Ltd. | Heterocyclic compound, and pharmaceutical composition thereof, preparation method therefor, intermediate thereof and application thereof |
| EP4114528A1 (en) * | 2020-03-06 | 2023-01-11 | Bayer Aktiengesellschaft | Imidazotriazines acting on cancer via inhibition of cdk12 |
| CN112079781B (zh) * | 2020-09-30 | 2022-11-22 | 苏州康润医药有限公司 | 5-溴-1-甲基-1h-吡唑-3-胺的合成方法 |
| EP4255909A1 (en) * | 2020-12-02 | 2023-10-11 | Qurient Co. Ltd. | Compounds having cyclin-dependent kinase(cdk)-inhibitory function |
| GB202108572D0 (en) * | 2021-06-16 | 2021-07-28 | Carrick Therapeutics Ltd | Therapeutic compounds and their use |
| CN114195710A (zh) * | 2021-12-20 | 2022-03-18 | 上海彩迩文生化科技有限公司 | 一种喹啉类胺甲基化合物的制备方法 |
| KR20240112230A (ko) * | 2023-01-11 | 2024-07-18 | 주식회사 티움바이오 | 사이클린 의존성 키나아제 9 저해제로서의 피라졸로피리미딘 유도체 |
| WO2024175024A1 (zh) * | 2023-02-21 | 2024-08-29 | 杭州德睿智药科技有限公司 | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 |
| CN117756747A (zh) * | 2023-12-21 | 2024-03-26 | 济宁医学院 | 一种n-苯基含氮多元环季铵盐类化合物的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US615968A (en) | 1898-12-13 | Apparatus for treating ores | ||
| US7205308B2 (en) * | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
| CN100376580C (zh) * | 2002-09-04 | 2008-03-26 | 先灵公司 | 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶 |
| US7563798B2 (en) * | 2002-09-04 | 2009-07-21 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| US8673924B2 (en) * | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| AR047969A1 (es) * | 2004-02-25 | 2006-03-15 | Schering Corp | Pirazolotriazinas como inhibidores de quinasa |
| JP2009007342A (ja) * | 2007-06-01 | 2009-01-15 | Mitsubishi Tanabe Pharma Corp | 医薬組成物 |
| EP2634190A1 (en) * | 2012-03-01 | 2013-09-04 | Lead Discovery Center GmbH | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors |
| EP2634189A1 (en) * | 2012-03-01 | 2013-09-04 | Lead Discovery Center GmbH | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors |
| GB201403093D0 (en) * | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EP3129371B1 (en) | 2014-04-05 | 2020-07-29 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CA2978170C (en) | 2015-03-09 | 2024-02-27 | Aurigene Discovery Technologies Limited | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors |
| WO2019144149A2 (en) * | 2018-01-22 | 2019-07-25 | Fred Hutchinson Cancer Research Center | Treatment methods for pancreatic tumors associated with the worst prognosis |
-
2019
- 2019-04-11 US US17/045,030 patent/US11945822B2/en active Active
- 2019-04-11 CN CN201980039582.5A patent/CN112313235A/zh active Pending
- 2019-04-11 JP JP2020555100A patent/JP2021521120A/ja active Pending
- 2019-04-11 SG SG11202009724YA patent/SG11202009724YA/en unknown
- 2019-04-11 IL IL277770A patent/IL277770B2/en unknown
- 2019-04-11 MX MX2020010675A patent/MX2020010675A/es unknown
- 2019-04-11 CA CA3095880A patent/CA3095880A1/en active Pending
- 2019-04-11 BR BR112020020768-3A patent/BR112020020768A2/pt unknown
- 2019-04-11 EP EP19720425.8A patent/EP3774810A1/en active Pending
- 2019-04-11 KR KR1020207032379A patent/KR20200141487A/ko unknown
- 2019-04-11 AU AU2019250507A patent/AU2019250507B2/en active Active
- 2019-04-11 WO PCT/EP2019/059302 patent/WO2019197549A1/en active Application Filing
-
2020
- 2020-10-05 PH PH12020551639A patent/PH12020551639A1/en unknown
-
2023
- 2023-08-14 JP JP2023131904A patent/JP2023138858A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021521120A (ja) | 2021-08-26 |
| WO2019197549A1 (en) | 2019-10-17 |
| EP3774810A1 (en) | 2021-02-17 |
| JP2023138858A (ja) | 2023-10-02 |
| AU2019250507A1 (en) | 2020-10-22 |
| MX2020010675A (es) | 2020-10-28 |
| CA3095880A1 (en) | 2019-10-17 |
| AU2019250507B2 (en) | 2023-09-28 |
| US20210147427A1 (en) | 2021-05-20 |
| IL277770B2 (en) | 2024-01-01 |
| CN112313235A (zh) | 2021-02-02 |
| IL277770A (en) | 2020-11-30 |
| IL277770B1 (en) | 2023-09-01 |
| PH12020551639A1 (en) | 2021-07-05 |
| BR112020020768A2 (pt) | 2021-01-19 |
| KR20200141487A (ko) | 2020-12-18 |
| US11945822B2 (en) | 2024-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277770A (en) | History of pyrazolo-triazine and/or pyrazolo-pyrimidine as selective inhibitors of cyclin-dependent kinase | |
| IL290399A (en) | kras g12c inhibitors and methods of using them | |
| IL272512A (en) | KRAS G12C inhibitors and methods of using them | |
| IL267495B (en) | kras g12c inhibitors and methods of using them | |
| SG11202002947TA (en) | Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same | |
| EP3728270A4 (en) | MACROCYCLIC KINASE INHIBITORS AND THEIR USES | |
| IL277600A (en) | AXLkinase inhibitors and their use | |
| EP3668839A4 (en) | HETEROCYCLIC INHIBITORS OF THE ATR KINASE | |
| EP3651768A4 (en) | HETEROCYCLIC INHIBITORS OF THE ATR KINASE | |
| SG10201913927VA (en) | Kinase inhibitors and uses thereof | |
| EP3621615A4 (en) | APOPTOSIS 1 SIGNAL REGULATION KINASE INHIBITORS AND THEIR METHODS OF USE | |
| EP3600287A4 (en) | KINASE NETWORK INHIBITORS AND THEIR USES | |
| EP3265093A4 (en) | Tricyclic kinase inhibitors of melk and methods of use | |
| SI3255046T1 (sl) | Hidroksietil sulfonat zaviralca od ciklina odvisne protein-kinaze, njegova kristalinična oblika in postopek priprave le-teh | |
| IL282588A (en) | Heterocyclic kinase inhibitors and their use | |
| SG11202104609SA (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| EP3284746A4 (en) | Preparation and use of kinase inhibitor | |
| EP3407885A4 (en) | TRIAZOLE DERIVATIVES OF MELAMPOMAGNOLIDE B AND METHODS OF USE THEREOF | |
| IL269144A (en) | Pyrrolotriazine derivatives as kinase inhibitors | |
| EP3717475A4 (en) | KINASEINHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | |
| EP3248979A4 (en) | Novel inhibitor of flt3 kinase and use thereof | |
| EP3752518A4 (en) | CYCLINE DEPENDENT KINASE INHIBITORS AND METHOD OF USING | |
| EP3752517A4 (en) | CYCLINE DEPENDENT KINASE DEGRADATION AGENTS AND METHODS OF USE | |
| EP3860999C0 (en) | RELEBACTAM DERIVATIVES AND THEIR USES | |
| GB201705201D0 (en) | Novel compounds and their use as kinase inhibitors |